FDA Warning Wire: Bevy Of Big-Name Cos. Targeted
CSL Behring Scolded for Hemophilia Promo
Perhaps the most notable action targeted biotech company CSL Behring LLC over promotional efforts for hemophilia treatment Idelvion. The company received a so-called untitled letter from the advertising office in the FDA's Center for Biologics...
To view the full article, register now.